88results about How to "Reduce phagocytosis" patented technology

The invention provides a targeted photothermal black phosphorus nano-preparation, which is prepared from a black phosphorus nano-slice, polyethylene glycol absorbed on the surface of the black phosphorus nano-slice by means of electrostatic attraction, and folic acid connected to the polyethylene glycol by means of an amide bond, wherein one end of the polyethylene glycol is amino, and the other end of the polyethylene glycol is imino; nitrogen atom of the imino and carbonyl carbon atom of the folic acid are connected with each other so as to form the amide bond; the folic acid is exposed at the outermost layer of the nano-preparation. The targeted photothermal black phosphorus nano-preparation is high in stability, good in target recognition ability and excellent in light-heat property, is capable of effectively killing cancer cells, and can be used for performing targeted photothermal treatment on cancers at the cellular level. The invention also provides a preparation method and application of the targeted photothermal black phosphorus nano-preparation.

The invention relates to a bio-degradable alb derivative and the related pharmaceutical combinations; wherein, the derivative introduces alkyl, or fatty acyl or deoxycholic acid in the alb skeleton to enable the amphiphilic property and form a nano-micelle by self-organization in water, and can enwrap the drugs through the double effects of the hydrophobic group, the alb molecular chain and the drugs, thereby substantially improving the drug enwrapping ability of the alb and prolonging the stability time. The excipient can be used as the carrier for organic drugs, water-insoluble drugs or dugs with poor water solubility and the carrier of amphipathic drugs, and for the administration inside the vein or muscle injection and oral administration. The preparation method of the bio-degradable alb derivative and the related pharmaceutical combinations is simple and of mature techniques, which is suitable for large scale continuous production.

The invention relates to a biodegradable amphiphilic albumin derivative and a pharmaceutical composition thereof. In the biodegradable amphiphilic albumin derivative, hydrophilic long-chain polyethyleneglycol and alkyl (acyl) group or (deoxidized) cholic acid are led to an albumin skeleton so that the amphiphilic albumin derivative is amphipathic and is self-assembled in water to form nano-micelle. The biodegradable amphiphilic albumin derivative is characterized in that medicament can be encapsulated through the double actions of a hydrophobic group and an albumin molecule chain with the medicament, and the capacity of the albumin encapsulating the medicament is markedly improved; in addition, a hydrophilic long-chain can reduce the immunogenicity of the albumin and improve the nano-micelle surface hydrophilicity so that the stability of the nano-micelle in aqueous medium can be improved and the nano-micelle has long-circulation characteristics in a body. The pharmaceutical composition of the biodegradable amphiphilic albumin derivative can be used as the carrier of organic medicament, water-insoluble or insoluble medicament and amphiphilic medicament, can be used for intravascular administration, intramuscular injection administration, oral administration, cavitary administration or external administration. The invention can be prepared with simple method and mature process and is suitable of large-scale continuous production.

The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.

The invention provides a reduction-sensitive-type water-soluble molecularly-targeted photosensitizer. The photosensitizer is a conjugate which is formed by sequentially connecting meso-tetrahydroxy phenyl chlorine (mTHPC) with a folic acid group through a carbonic ester bond, a disulfide bond and a PEG chain. The invention further provides a chlorine intermediate and a folic acid PEG cysteine amide intermediate which are used for preparing the photosensitizer and a preparation method of the targeted photosensitizer. According to the photosensitizer which has the good tumor targeting performance, the photodynamic activity and water solubility, by introducing the disulfide bond and the carbonic ester bond into the molecular structure, the targeted photosensitizer can generate an exchange reaction of a sulfydryl and the disulfide bond and a nucleophilic substitution reaction in molecules in a strong reducing environment of a tumor cell after entering the cell, therefore, the mTHPC is completely released, and it is guaranteed that the photodynamic activity of the mTHPC cannot be reduced due to the structural change.

The invention relates to a dissolving ultrafiltration-spray drying-molecule dispersion coating-hydration palletizing-freeze drying method, which can industrially prepare both liposome medicine-carrying injections and liposome medicine-carrying oral preparations by utilizing uniform prescriptions, technologies and devices. The invention provides a mole-ratio prescription of various components and materials for preparing liposome medicine-carrying preparations, and provides a technology for preparing nanoliposome lyophilization injections and liposome oral preparations. The invention also provides 20 embodiments for preparing liposome medicine-carrying preparations: an embodiment for preparing anti-gastric-ulcer liposome medicine-carrying preparations, an embodiment for preparing antibiosis and anti-fungus liposome medicine-carrying preparations, an embodiment for preparing anti-tumor liposome medicine-carrying preparations, an embodiment for preparing anti-viral liposome medicine-carrying preparations, an embodiment for preparing anti-emetic liposome medicine-carrying preparations, an embodiment for preparing nutrition-supplement liposome medicine-carrying preparations and an embodiment for preparing anti-diabetics and cardio- and cerebro-vascular drug liposome medicine-carrying preparations.

The invention is a polypeptide protein type oral nano granular preparation. It uses polymer or amphiphatic compound as coating material, and uses the hydrogenous bonds formed between the surfactants absorbed on the interface of the coating material and the oil-water, for examples, the amido in the swelling chitosan molecule in the chitosan coating polyester nano granule and the oxygen atom or the alcohol hydroxyl in the hydrophilic ehenoxy group form the hydrogenous bonds to make it; or the chitosan directly makes the gelation reaction with the multivalent anions to make the nano-granular preparation.

The invention relates to a preparation method of a pH value-sensitive curcumin-loading micelle (single chain) precursor. The chemical formula of the pH avid-sensitive curcumin micelle (single chain) precursor is MPEG-PLA-N=Cur. The preparation method comprises the following steps: dissolving modified methoxy poly(ethylene glycol)-poly(lactic acid) of which the terminal contains hydrazino and single-terminal phenolic hydroxyl carbonylated curcumin serving as reaction raw materials in a proper feeding ratio under the action of a certain solvent; carrying out a bonding reaction to form a pH avid-sensitive curcumin micelle monomer. Compared with the prior art, the preparation method has the advantages that a hydrazone bond is introduced into the conventional diblock copolymer (MPEG-PLA) structure and is bonded with curcumin which is a hydrophobic medicament, and a formed amphiphilic polymer is self-assembled into a micelle in an aqueous solution.

According to the invention, a liposome combination drug injection and an oral liposome combination drug preparation can be produced in a large industrialization manner through a molecular dispersion method with a unified formula, a unified process and unified equipment. The invention provides a formula of raw components for preparing liposome combination drugs in a molar ratio, provides freeze-drying injection and oral preparation processes for the prepared liposome combination drugs, and also provides twenty embodiments for preparing the liposome combination drugs, such as an anti-gastric-ulcer liposome combination drug, antibacterial and antifungal liposome combination drugs, an anti-tumor liposome combination drug, an anti-virus liposome combination drug, an anti-emetic liposome combination drug, a nutritional supplement liposome combination drug and hypoglycemic agent and cardiovascular medicine liposome combination drugs.

The invention relates to a macrophage-mediated drug-loaded hyaluronic acid nanohydrogel and preparation thereof. A drug-loaded hyaluronic acid nanohydrogel is obtained by synthesizing polypyrrole in situ from the interior of a hyaluronic acid nanohydrogel, and loading a drug; and the macrophage-covered drug-loaded nanohydrogel is obtained by performing co-incubation on the drug-loaded hyaluronic acid nanohydrogel and mouse macrophages. The macrophage-mediated drug-loaded nanohydrogel prepared by the method has the advantages of low toxicity, safety, avoidance of phagocytosis of a reticuloendothelial system, and specific targeting in tumor areas when used for delivery of anti-cancer drugs, and has potential application prospects in tumor treatment.

A method and composition for artificial insemination. The method involves artificially inseminating the subject with sperm, wherein the sperm is combined or coadministered with an inhibitor of phosphodiesterase and preferably a soluble salt of an earth alkaline metal. The composition comprises phosphodiesterase inhibitor or a functional equivalent thereof, a soluble salt of an earth alkaline metal and sperm. The method and composition reduce the recruitment of polymorphonuclear neutrophils.

The invention belongs to the field of pharmaceutical preparations, and relates to a deoxypodophyllotoxin medicine-containing pharmaceutical composition and a preparation method and a preparation thereof. The deoxypodophyllotoxin medicine-containing pharmaceutical composition comprises a deoxypodophyllotoxin medicine and hyaluronic acid-5 beta cholanic acid, and the hyaluronic acid-5 beta cholanic acid coats the deoxypodophyllotoxin medicine in micellar form. The invention also discloses the preparation method and application of the pharmaceutical composition. The deoxypodophyllotoxin medicine-containing pharmaceutical composition has excellent tumor targeting property and good safety, reduces the toxic and side effects, improves the curative effect, can be used for intravenous injection, and has good application prospect in tumor target drug application system research and tumor treatment.

A freeze-dried macrocyclic vesicle for preventing and treating cancer is proportionally prepared from 10-hydroxy camptothecine, PEG modified lipoid, span, cholesterol, trehalose or cane sugar, alcohol and dichloromethane. Its advantages are high water solubility and stability, and low toxin.

The invention provides a bi-modal tumor targeted nano particle photographic developer and a method for preparing the bi-modal tumor targeted nano particle photographic developer. Near-Infrared fluorescence core-cross-linked polymeric micelles (NIRF-CCPM) with good biological performance serve as a carrier, coupling of polypeptide RGD (arginine-glycine-aspartic acid) with tumor targeting and nano particles is carried out to obtain a novel tumor targeting nano molecular imaging probe NIRF-CCPM-RGD, labeling is conducted on the NIRF-CCPM-RGD through a radionuclide 111In to obtain 111In-NIRF-CCPM-RGD, specific binding can be conducted on the 111In-NIRF-CCPM-RGD and an antigen alpha v beta 3 of a tumor neoangiogenesis endothelial cell, a tissue with high expression through the alpha v beta 3 is accurately positioned respectively through an infrared mode and a nuclear medicine mode to achieve tumor targeting molecule image diagnoses, and researches of a plurality of molecule image probes are conducted on the same molecule to achieve tumor early detection, early diagnosing and early treatment targets.

The invention belongs to the field of molecular imaging probes and particularly relates to a preparation method of a dual-modal nano imaging drug Dex-Rho-99mTc based on glucan, and an application of the drug in imaging diagnosis. The general formula of the drug is Rho-Dex-PEG-DTPA-99mTc, wherein the Dex represents for the glucan of which the molecular weight is 10-100k, the PEG represents for polyethylene glycol of which the molecular weight is 1-10k, the Rho represents for a fluorescent group rhodamine, the DTPA is a chelating agent of an imaging nuclide and the 99mTc is a radioisotope Technetium-99 used for SPECT imaging. In the invention, the surface of the high-molecular material glucan is modified by a certain number of amino groups and the PEG, the fluorescent group and the SPECT imaging groups are connected to the glucan supporter through the amino groups and finally the drug is marked by the radioisotope [99mTc]. The drug is good in biocompatibility, is simple in the preparation method, is safe and convenient to use and can be employed in dual-modal imaging. The dual-modal nano imaging drug has wide application prospects in the biomedical fields of early diagnosis of cancer, medicine delivery under guide of imaging, noninvasive iconography curative effect evaluation and the like.

The invention belongs to the technical field of bioengineering and provides a biological medicament that has recombinant gene expression of helicoverpa armigera C-type lectin and two carbohydrate recognizing structural domains of Ha-CRD1 and Ha-CRD2 of the gene. The helicoverpa armigera C-type lectin gene and the two carbohydrate recognizing structural domains of Ha-CRD1 and Ha-CRD2 of the gene have recombinant expression in Escherichia coli. The invention further provides a recombinant gene expression method of the helicoverpa armigera C-type lectin and the two carbohydrate recognizing structural domains of Ha-CRD1 and Ha-CRD2 of the gene. The lectin can reduce the insect fatal rate of pathogenic organisms, improve the pathogenic organism phagocytizing efficiency of blood corpuscle, and reduce the survival number of pathogenic organisms in insect bodies. The biological medicament does not generate drug-fast bacteria, does not have adverse effect to the normal vital activity of insects, can reduce the usage of antibiotic, and can reduce the drug-fast bacteria generation in environments.

The invention provides a novel bionic nano material for sonodynamic/gas synergistic anti-tumor treatment. Gold nanoparticles (AuNPs) are loaded in situ by using black phosphorus quantum dot hybrid mesoporous silicon nanoparticles, and CO gas prodrug molecules CORM-401 are loaded by using rich porous structure advantages of the gold nanoparticles, and a macrophage membrane is further used for wrapping to obtain the bionic nano material N-coated CAu-BMSN. The utilization of the macrophage membranes in the bionic nano-material can effectively avoid the phagocytosis and removal effects of macrophages in vivo on N-coated CAu-BMSN, and improve the enrichment of the nano-material in a tumor area; and meanwhile, under the intervention of local ultrasonic waves, CO gas and 1O2 can be effectively generated in tumor cells in situ by the nano-material core and are used for inducing tumor cell apoptosis and activating an organism immune system, thereby realizing sonodynamic/gas synergistic anti-tumor treatment.

The invention relates to the fields of biological functional materials and nanotechnologies and particularly relates to a novel amphiphilic polymer nano medicine carrying micelle which is proper in particle size distribution range, stable in encapsulation rate and medicine carrying rate, high in biological safety and capable of increasing bioavailability of ursolic acid and a structural modifier thereof. The technical scheme of the invention provides a medicine carrying micelle capable of increasing bioavailability of ursolic acid and a structural modifier thereof. The medicine carrying micelle is characterized in that the preparation method comprises the following steps of 1, synthesizing PLGA-PEG-PLGA (poly(lactic-co-glycolic acid)-polyethylene glycol-poly(lactic-co-glycolic acid)) by using a ring opening polymerization method; 2, simultaneously dissolving an insoluble drug and a triblock copolymer into an organic solvent to prepare an oil phase; 3, dropwise adding the oil phase into a water phase stirred at a high speed; 4, stirring until the oil phase is completely volatilized, and filtering a membrane in the solution to obtain a medicine carrying nanoparticle contained ultrapure water solution; freezing and drying to obtain the medicine carrying micelles.

The invention provides a vincristine-PEG-PLGA segmented copolymer nanoparticle for incorporating vincristine into PEG-PLGA segmented copolymer, also provides a method for preparing the nanoparticle by emulsification-solvent evaporation method and other methods, and use of the nanoparticle in preparing anticancer drug. The nanoparticle provided by the invention can improve the solubility of drugs effectively; can avoid dose dumping and incomplete release to allow the drug to release slowly; can reduce the abilities of RES to identificate and phagocytose nanoparticle, so as to realize the targeted release of the drug in tissues and organs out of the reticuloendothelial system; can reduce toxic and side effect, increase biocompatibility, prolong the circulation time of the drug in the blood; and can increase the compliance of the patients.

The invention relates to biodegradable recombinant human serum albumin amphipathic derivatives and preparation and application of a medicinal composition thereof. For the derivatives, alkyl is introduced onto a recombinant human serum albumin skeleton, so that the recombinant human serum albumin skeleton has amphipathy, and is automatically assembled to form nano micelles in water. The biodegradable recombinant human serum albumin amphipathic derivatives have the characteristics that: a medicament can be coated by double interaction between a hydrophobic alkyl (acyl) chain and a recombinant human serum albumin molecular hydrophobic chain and the medicament; and the capability of coating the medicament by using recombinant human serum albumin is obviously improved. Auxiliary materials have high safety. Diseases can be prevented from spreading by protein sources. The biodegradable recombinant human serum albumin amphipathic derivatives can be used as vectors of an organic medicament, an insoluble or slightly soluble medicament and an amphipathic medicament and are used for intravascular or intramuscular injection, oral administration and cavitary or external administration. The medicinal composition has a simple preparation method and a mature process and is suitable for large-scale continuous production.